Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M R Stockler

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 30, 2019
Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patientsM E S Smith-Uffen, S B Johnson, A J Martin, et al.
British Journal of Cancer|April 10, 2014
Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancerH-M Lin, L Castillo, K L Mahon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)P S Grimison, M R Stockler, M Chatfield, et al.
Gynecologic Oncology|December 15, 2019
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS)F T Roncolato, R L O'Connell, F Joly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2015
EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinomaI D Davis, A Long, S Yip, et al.
British Journal of Cancer|April 14, 2015
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancerK L Mahon, H-M Lin, L Castillo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2013
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29S A Laurie, B J Solomon, L Seymour, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trialA Davidson, A-S Veillard, A Tognela, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 22, 2025
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)H-M Lin, T Scheinberg, N Portman, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 30, 2019
Estimating survival in advanced cancer: a comparison of estimates made by oncologists and patientsM E S Smith-Uffen, S B Johnson, A J Martin, et al.
British Journal of Cancer|April 10, 2014
Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancerH-M Lin, L Castillo, K L Mahon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2013
Accelerated BEP for metastatic germ cell tumours: a multicenter phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)P S Grimison, M R Stockler, M Chatfield, et al.
Gynecologic Oncology|December 15, 2019
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS)F T Roncolato, R L O'Connell, F Joly, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 22, 2015
EVERSUN: a phase 2 trial of alternating sunitinib and everolimus as first-line therapy for advanced renal cell carcinomaI D Davis, A Long, S Yip, et al.
British Journal of Cancer|April 14, 2015
Cytokine profiling of docetaxel-resistant castration-resistant prostate cancerK L Mahon, H-M Lin, L Castillo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2013
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29S A Laurie, B J Solomon, L Seymour, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 9, 2015
A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trialA Davidson, A-S Veillard, A Tognela, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 22, 2025
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)H-M Lin, T Scheinberg, N Portman, et al.
Pageof 5